Summary of clinical characteristics and survival data of patients with tumor-stage MF (stage IIB) with or without lLCT at presentation
| . | MF stage IIB with LCT at presentation (n = 25) . | MF stage IIB without LCT at presentation (n = 27) . |
|---|---|---|
| Male/female | 16/9 | 23/4 |
| Median age, y (range) | 72 (42-90) | 63 (40-82) |
| CD30 expression | ||
| Positive (> 50% of blast cells, %) | 13/25 (52) | |
| Negative (< 50% of blast cells, %) | 12/25 (48) | —* |
| Folliculotropic MF (%) | 10/25 (40) | 13/27 (59) |
| Extent of skin lesions | ||
| Solitary (%) | 8/25 (32) | 8/27 (30) |
| Regional/localized (%) | 9/25 (36) | 8/27 (30) |
| Generalized (%) | 8/25 (32) | 11/27 (40) |
| Median survival, mo (range) | 42 (5-153) | 53 (12-262) |
| 2-y DSS/OS, % | 95/75 | 88/84 |
| 5-y DSS/OS, % | 56/40 | 54/48 |
| 10-y DSS/OS, % | 56/30 | 29/16 |
| P value DSS/OS | .644/.721 | |
| . | MF stage IIB with LCT at presentation (n = 25) . | MF stage IIB without LCT at presentation (n = 27) . |
|---|---|---|
| Male/female | 16/9 | 23/4 |
| Median age, y (range) | 72 (42-90) | 63 (40-82) |
| CD30 expression | ||
| Positive (> 50% of blast cells, %) | 13/25 (52) | |
| Negative (< 50% of blast cells, %) | 12/25 (48) | —* |
| Folliculotropic MF (%) | 10/25 (40) | 13/27 (59) |
| Extent of skin lesions | ||
| Solitary (%) | 8/25 (32) | 8/27 (30) |
| Regional/localized (%) | 9/25 (36) | 8/27 (30) |
| Generalized (%) | 8/25 (32) | 11/27 (40) |
| Median survival, mo (range) | 42 (5-153) | 53 (12-262) |
| 2-y DSS/OS, % | 95/75 | 88/84 |
| 5-y DSS/OS, % | 56/40 | 54/48 |
| 10-y DSS/OS, % | 56/30 | 29/16 |
| P value DSS/OS | .644/.721 | |
In most cases scattered CD30+ blast cells (< 1%-5% of total infiltrate).